MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

32.65 3.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.29

Max

33.4

Belangrijke statistieken
By Trading Economics
Inkomsten	638K -65M
Verkoop	7.5M 7.5M
Winstmarge	-867.293
Werknemers	316
EBITDA	4.1M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+76.1% upside

Dividenden
By Dow Jones
Volgende Winsten	7 aug 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-303M 2.4B
Vorige openingsprijs	28.67
Vorige sluitingsprijs	32.65

Nieuwssentiment

By Acuity

68%

32%

343 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jul 2025, 15:46 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Marktinformatie

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Winsten

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Marktinformatie

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Marktinformatie

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Acquisities, Fusies, Overnames

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Marktinformatie

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Marktinformatie

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Marktinformatie

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Acquisities, Fusies, Overnames

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Acquisities, Fusies, Overnames

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Marktinformatie

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

76.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.33 USD 76.1%

Hoogste 65 USD

Laagste 47 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

343 / 376 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.